Allergic Contact Dermatitis
Oncology·MeSH: Dermatitis, Allergic Contact
Prevalence
1977.4 / 100K
Incidence
5459.9 / 100K/yr
1 drug in development·1 company·0 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| eb01 | Edesa Biotech, Inc. (EDSA) |
Frequently asked questions
How many drugs are in development for Allergic Contact Dermatitis?
BioSniper tracks 1 drug in development for Allergic Contact Dermatitis across 1 company.
What is the prevalence of Allergic Contact Dermatitis?
The estimated prevalence of Allergic Contact Dermatitis is approximately 1977.4 per 100,000 population.
Deep-dive into Allergic Contact Dermatitis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis